- Home
- AEMD vs GLMD Comparison
AEMD vs GLMD Comparison
Compare AEMD & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- GLMD
- Stock Information
- Founded
- AEMD 1984
- GLMD 2000
- Country
- AEMD United States
- GLMD Israel
- Employees
- AEMD N/A
- GLMD N/A
- Industry
- AEMD Medical/Dental Instruments
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- GLMD Health Care
- Exchange
- AEMD Nasdaq
- GLMD Nasdaq
- Market Cap
- AEMD 4.1M
- GLMD 4.1M
- IPO Year
- AEMD N/A
- GLMD 2014
- Fundamental
- Price
- AEMD $1.14
- GLMD $1.44
- Analyst Decision
- AEMD Buy
- GLMD Hold
- Analyst Count
- AEMD 2
- GLMD 1
- Target Price
- AEMD $28.75
- GLMD N/A
- AVG Volume (30 Days)
- AEMD 126.6K
- GLMD 229.4K
- Earning Date
- AEMD 08-13-2025
- GLMD 08-27-2025
- Dividend Yield
- AEMD N/A
- GLMD N/A
- EPS Growth
- AEMD N/A
- GLMD N/A
- EPS
- AEMD N/A
- GLMD N/A
- Revenue
- AEMD N/A
- GLMD N/A
- Revenue This Year
- AEMD N/A
- GLMD N/A
- Revenue Next Year
- AEMD N/A
- GLMD N/A
- P/E Ratio
- AEMD N/A
- GLMD N/A
- Revenue Growth
- AEMD N/A
- GLMD N/A
- 52 Week Low
- AEMD $1.09
- GLMD $1.15
- 52 Week High
- AEMD $8.44
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- AEMD 38.81
- GLMD 39.22
- Support Level
- AEMD $1.09
- GLMD $1.38
- Resistance Level
- AEMD $1.41
- GLMD $1.52
- Average True Range (ATR)
- AEMD 0.09
- GLMD 0.11
- MACD
- AEMD 0.02
- GLMD -0.02
- Stochastic Oscillator
- AEMD 15.62
- GLMD 19.41
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.